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DEVELOPMENT OF A TESTICULAR CANCER VACCINE 
 
ROBERTO AGUILAR III 
 
ABSTRACT 
 
Testicular cancer mainly affects men between the ages of 20 and 35 but is the 
most common male neoplasm between the ages of 15 and 34.  The National 
Cancer Institute (NCI) states that localized testicular cancer has a recurrence 
rate of 15-20% and tumors that are Sertoli or Leydig cell derived fail to respond 
to chemotherapy or radiation treatments.  The recurrence rate may increase to 
32% if at diagnosis the tumor is greater than 4 cm in size with invasion of the rete 
testes.  To improve therapy for testicular cancer, we examined the usefulness of 
a testicular cancer vaccine.  We reasoned that such a vaccine may strengthen 
the body’s natural oncologic defenses and assist in the elimination of local and 
systemic metastases.  Also, the vaccine could be administered as adjuvant 
therapy in conjunction with current standard of care involving surgery and 
chemotherapy.   
 
Inhibin-α is a protein involved in spermatogenesis and is secreted by Sertoli and 
Leydig cells of the testes. Inhibin-α is also expressed in many testicular tumors. 
We found that vaccination against recombinant mouse inhibin-α provides 
protection and therapy against transplantable I-10 mouse testicular tumors in 
male BALB/c mice. Similarly, we found that vaccination with the immunogenic 
p215-234 peptide of inhibin-α (Inα 215-234) provides protection and therapy 
  ix 
against the growth of autochthonous testicular tumors that grow spontaneously in 
male SJL.AMH-SV40Tag transgenic mice. Our results provide a rational basis for 
developing immune control of testicular cancer. 
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CHAPTER I 
BACKGROUND AND INTRODUCTION 
 
TESTICULAR CANCER 
 
Classification of Testicular Cancer 
Testicular cancer is a malignancy forming in the tissues of one or both testicles 
(Testicular Cancer, 2015).  There are three main types of testicular cancers; 
seminomas, non-seminomas, and gonadal stromal tumors.  Seminomas arise 
from sperm-producing germ cells of the testicles and occur in men between the 
ages of 30 and 50.  Non-seminomas consist of four subclasses: embryonal 
carcinomas, yolk sac carcinomas, choriocarcinomas, and teratomas.  Non-
seminomas may consist of any one or a mix of these four subclasses and occur 
in men between their teens and early 40s.  Gonadal stromal tumors develop in 
the hormone-producing cells of the stroma and account for 20% of childhood 
cases (Testicular Cancer, 2015).  Some originate from the stromal interstitial 
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space where the Leydig cells reside.  Leydig cells secrete hormones that 
regulate spermatogenesis; one hormone in particular, inhibin, is known to be 
overexpressed in testicular tumors (Bhat et al., 2013).      
  
Treatment 
Testicular tumors are treated using one of three traditional methods: 1. Surgery 
involving radical inguinal orchiectomy, or removal of the testicle through an 
incision in the groin; 2. Local radiotherapy that employs high energy X-rays to 
destroy cancer cells but may also destroy normal cells; 3. Chemotherapy, which 
is the most common systemic cytostatic that targets hyperproliferating cells found 
in tumors but may also have deleterious effects on normal tissues of high mitotic 
index, e.g., bone marrow, hair, and intestinal epithelia (Testicular Cancer 
Treatment, 2015).  Gonadal stromal tumor metastases have a poor prognosis 
because they are unresponsive to chemo- or radiation therapy (Testicular Cancer 
Treatment, 2015).  Despite radical inguinal orchiectomy, there is a 15% chance 
of relapse which can increase to 32% if the tumor is greater than 4cm in size and 
invasion of the rete testis has occurred (Testicular Cancer Treatment, 2015).  An 
optional adjuvant vaccine that strengthens the treatment for testicular cancer 
could shift the prognosis in favor of the patient.   
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Cancer Vaccines 
There are two different concepts for vaccination; whole tumor homogenates or 
defined tumor peptides.  Historic achievements in immunization, such as those 
obtained from the smallpox and polio vaccines, have inspired scientists to 
attempt the immunization of cancer patients to their own cancer cells 
(Rosenberg, 2001).  Homologized vaccines involve the immunization with 
autologous or allogenic intact tumor cells or intracellular extracts but present a 
problem due to the limited quantity of immunogenic whole tumor cell surface and 
intracellular antigens (Rosenberg, 2001).  Various attempts have been made to 
enhance the immunogenicity of whole tumor homogenates by mixing them in a 
variety of adjuvants or through the transduction of cytokine genes.  Despite such 
determination, it has been difficult to detect a specific immune response to the 
vaccine and gauge its efficacy using whole tumor cell homogenates (Rosenberg, 
2001).   
 
Some promising results have been obtained with the use of defined tumor 
peptides such as melanoma antigen E-3, cancer/testis antigen 1B, melanocyte 
and melanoma antigens, tyrosinase, and glycoprotein 100 (gp100) from 
malignant testicles.  Tumor antigens have been used alone or combined with 
cytokines such as interleukins 2 or 12 (IL-2, IL-12) or with an adjuvant (i.e. 
incomplete Freund’s adjuvant) in order to increase their immunogenicity (Jager et 
al., 2000; Marchand et al., 1999).  Different combinations of tumor antigens and 
cytokines did produce measurable peptide-specific immune responses of CD8+ T 
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cells resulting in tumor remission (Jager et al., 2000; Marchand et al., 1999).  
Recombinant virus constructs such as adenovirus and vaccinia virus have also 
been attempted but with poor results probably due to the presence of anti-viral 
proteins in the participating cancer patients.  Dendritic cells transfected with 
recombinant viruses have delivered some promising results but due to their 
copious antigen repertoire, the immunological responses have been difficult to 
gauge (Jager et al., 2000; Marchand et al., 1999).        
 
AUTOIMMUNITY 
 
Organ-Specific Autoimmunity 
Exogenous bacteria and viruses are, under the best of circumstances, attacked 
and disposed of by human immune cells.  However, flaws in immune cells can 
result in an attack on “self” resulting in an organ specific or systemic autoimmune 
disease.  Some organs such as the pancreas, salivary glands, and joints are 
specifically vulnerable to autoimmune attacks (Ishimaru, 2012).  Type 1 Diabetes 
is an example of an organ-specific autoimmune disease and is now one of the 
most common chronic diseases among children.  The self-recognition response 
is restricted to proteins found in the beta cells of the pancreatic islets therefore 
eliminating insulin production (Atkinson, 2014).            
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THE TESTICLE 
 
Basic Anatomy and Physiology 
The testicles are enclosed within a dual-chambered sack called the scrotum and 
consist of highly coiled tubes known as seminiferous tubules where meiotic 
divisions give rise to spermatozoa.  The lumen of the seminiferous tubules is only 
apparent if a sagittal section (dotted line) of a testicle is taken (Figure 1.1A).  The 
tubules appear as ovoid cords separated by cell groups within the interstitial 
space (Figure 1.1B).  Increased magnification (arrow) reveals Sertoli and germ 
cells within the seminiferous tubules.  Sertoli cells play an intricate role in sperm 
maturation and also form the blood-testis-barrier.  Spermatogenesis is regulated 
by the Leydig cells found within the interstitial space (Figure 1.1C). 
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FIGURE 1.1 Histological characterization and evaluation of testicular cells.  
(A), Basic anatomy of a testicle depicting where mouse testicles were sectioned 
(dotted line), fixed, and then embedded in paraffin (Gray’s Anatomy, 2010). (B) 
H&E stain of sectioned normal seminiferous tubules with black arrow indicating 
the interstitial space. (C) H&E stain of interstitial space depicting normal germ, 
Leydig and Sertoli cells.  Bar, 25 μm.   
 
 
 
 
 
  7 
Figure 1.2 illustrates the hormonal control of the male reproductive system. 
Beginning at puberty, the hypothalamus secretes Gonadotropin Releasing 
Hormone (GnRH) which then stimulates the anterior pituitary causing the release 
of the gonadotropins, Follicle Stimulating Hormone (FSH) and Luteinizing 
Hormone (LH).  FSH binds to target receptors on Sertoli cells which aid in 
spermatogenesis by nourishing the developing germ cells.  LH targets receptors 
on Leydig cells where it promotes the release of testosterone further encouraging 
spermatogenesis.  Once the spermatic threshold has been reached, Sertoli cells 
produce the hormone inhibin which then feeds back to the anterior pituitary 
where it inhibits the secretion and synthesis of FSH leading to a reduction in 
spermatogenesis (Griswold, 1998).  Testosterone has similar effects on 
spermatogenesis by binding to receptors within the hypothalamus and the 
anterior pituitary where it inhibits the release of LH.  Anti- Müllerian hormone is 
also secreted by Sertoli cells during embryonic development in males, preventing 
the formation of the Müllerian ducts which would otherwise grow to form the 
oviducts, uterus, and cervix in females (Jamin et al., 2003).        
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FIGURE 1.2 Hormonal control of the testicles.  Inhibin is a hormone that is 
secreted by the Sertoli cells and is involved with the control of spermatogenesis.  
It inhibits the synthesis and subsequent secretion of Follicle Stimulating Hormone 
(FSH) which in turn reduces spermatogenesis.  Anti-Müllerian Hormone (AMH) is 
also secreted by the Sertoli cells and is responsible in preventing the formation of 
the Müllerian ducts during embryonic development (Campbell et al., 2013). 
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THE INHIBINS 
 
Structure and Function 
The inhibins are proteins secreted by Sertoli and Leydig cells that decrease 
pituitary release of follicle stimulating hormone (FSH). Inhibins are heterodimeric 
glycoproteins that contain a single α-chain and one of two β-chain forms (Figure 
1.3A) held together by a single disulfide bond (Figure 1.3B).  Thus, there are two 
inhibins, namely inhibin A (α:βA) and inhibin B (α:βB) that belong to the 
transforming growth factor-β (TGFβ) superfamily (Kingsley, 1994; Vale et al., 
1994).  As such, the inhibins are important regulators of spermatogenesis.   
 
Inhibins are synthesized from large precursor proteins which consist of an N-
terminus prodomain and a mature C-terminus domain.  The prodomain contains 
hydrophobic residues (22-41) that interact noncovalently with regions in the 
mature domain (Figure 1.3C); this helps maintain the inhibin molecule in a 
conformation competent for dimerization.  Dimerization is also achieved through 
C-terminus noncovalent interactions of the prodomains (Walton et. al., 2011).  
Convertases then cleave the prodomains from the mature dimer which still 
remain noncovalently associated with the mature growth factor.  Once secreted, 
high-affinity interactions with the corresponding receptor protein cause the 
prodomain to dissociate from the mature ligand (Walton et. al., 2011).  
 
  10 
FSH production is blocked by inhibin in both males and females but the protein 
originates from different organs.  In the female, inhibin is produced by the 
pituitary gland, the gonads, placenta, and the corpus luteum while in the male, it 
is produced by both Sertoli and Leydig cells (Luisi et al., 2005).  Several inhibin-α 
peptides have been shown to be immunogenic and capable of inducing a CD4+ 
T cell response in female and male transgenic mice (Amor et al., 1994; Holz et 
al., 2000; Tuohy & Thomas, 1995).   
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FIGURE 1.3 The structure of inhibin.  (A) Testicular inhibin exists as a 
heterodimeric glycoprotein complex that includes an alpha and one of two β-
chain forms (βA or βB).  (B) Both subunits are held together by a single disulfide 
bond (Altuntas, 2005).  (C) Kyte-Doolittle hydrophobicity plot indicating inhibin-α 
hydrophobic regions. 
 
 
 
 
A 
B 
C 
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MOUSE MODELS FOR TESTICULAR TUMORIGENESIS AND THERAPY  
Animal models are useful for studying human disease and can therefore play an 
integral role in cancer research.  For example, Fowler et.al., 2000 developed a 
mouse model for testicular tumorigenesis using aromatase transgenic mice 
referred to as MMTV-int-5/aromatase.  They used a region of mouse mammary 
tumor virus promoter (MMTV-LTR) to drive the expression of aromatase.  MMTV-
LTR is expressed in male reproductive organs and mammary tissues therefore 
resulting in the overexpression of aromatase leading to increased estrogen 
production and subsequent induction of Leydig cell derived testicular cancer 
(Fowler et al., 2000).   
 
Construction of the Transgene and Transgenic Mice 
Dutertre et.al generated a transgenic mouse that develops autochthonous Sertoli 
cell tumors by using a transgene construct in which the human anti-Müllerian 
Hormone (hAMH) promoter regulates expression of the Simian Virus 40 Large 
Tumor Transformation Antigen (AMH-SV40TAg; Figure 1.4).  Previous 
investigations have determined that there is an element of the hAMH promoter 
which shares 80% homology with the murine sequence (Guerrier et al., 1990).  
Since the hAMH promoter would be turned on only in Sertoli cells, the resultant 
transgenic male mice would develop Sertoli cell tumors.  The transgene hosts 
were B6.D2 mice which are a cross between a C57BL/6 and a DBA/2J mouse.  
Zygotes of the B6.D2 mice were microinjected with the AMH-SV40TAg construct 
and then transferred into the oviduct of pseudopregnant B6.CBA females 
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(C57BL/6 and a CBA) resulting in transgenic mice denoted here as B6.D2.AMH-
SV40TAg (Figure 1.5).  The transgenic offspring were genotyped by PCR 
amplification of a part of the hAMH promoter (the 20% that is heterologous to the 
murine AMH sequence) in tail snips.  B6.D2.AMH-SV40TAg mice developed 
Sertoli cell derived macroscopic tumors at about 11 weeks of age (Dutertre et al., 
1997).  
 
 
 
 
FIGURE 1.4 Construction of the transgene.  The transgene construct 
developed by Dutertre et.al. 1997 contained the human Anti-Müllerian hormone 
promoter region fused to the Simian Virus 40 large tumor transformation antigen 
(AMH-SV40TAg).  
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FIGURE 1.5 Development of a mouse model for Sertoli cell tumorigenesis.  
The mice used by Dutertre et.al.,1997 were B6.D2 which are a cross between a 
C57BL/6 and a DBA/2J mouse.  The zygotes of B6D2 mice were microinjected 
with the Simian Virus 40 large tumor transformation antigen (AMH-SV40TAg) 
construct and were then transferred into the oviduct of pseudopregnant B6.CBA 
females (C57BL/6J x CBA) resulting in transgenic mice denoted here as 
B6.D2.AMH-SV40TAg.     
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Histological Aspect of Testicular Tumors from Transgenic Males 
Duertre et al., 1997 published histology images characterizing the B6.D2.AMH-
SV40TAg tumor model.  One image was of a testicle with dysplasia at an initial 
stage showing a normal seminiferous tubule flanked by two other tubules 
described as being devoid of germ cells and filled with proliferating Sertoli cells 
(Figure 1.6).  The second image was of cord-like structures deformed by 
malignant Sertoli cells (Figure 1.7).  
 
Duertre et al., 1997 also observed some instances where the basement 
membrane surrounding the seminiferous tubules was disrupted by Sertoli cells 
which then exited and invaded the interstitial space.  Sertoli cell tumor metastasis 
has also been described by Young et al., 1995 in two patients following a 
bilateral orchiectomy to remove Sertoli cell testicular tumors.  The neoplasms 
were composed of ovoid Sertoli-like cells with a large volume of cytoplasm and 
limited smooth endoplasmic reticulum.  Further microscopic examination of 
Sertoli tumors have also revealed large, solid masses composed of dilated 
tubules with hyalinized basement membranes filled with a pale eosinophilic-like 
cytoplasm (Young et al., 1998).      
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FIGURE 1.6 Histological aspect of Sertoli cell testicular tumors from 
transgenic males.  H&E stain published by Duertre et al., 1997.  Although it was 
labeled as an H&E stain, the original figure was in black and white.  Initial tumor 
stage showing a normal seminiferous tubule (*) and two neighboring tubules 
devoid of germ cells and filled with proliferating Sertoli cells (arrows).   
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FIGURE 1.7 Late stage Sertoli cell testicular tumors from transgenic males.  
H&E figure developed by Duertre et al., 1997 (originally published in black and 
white) showing a late stage testicular tumor with characteristic cord-like 
structures filled with Sertoli cells. 
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Testicular Cancer Vaccine 
It has become clear that an autoimmune attack sufficient to induce organ-specific 
failure can provide protection and therapy against tumors derived from the 
targeted organ (Dudley et al. 2002; Jaini et.al. 2010).  It is also well documented 
that Sertoli cells secrete inhibin-α, and therefore inhibin-α may be an effective 
and acceptable target for cancer vaccination especially if the resultant 
autoimmune consequences are tolerable.  We decided to use the mouse model 
for Sertoli cell tumorigenesis developed by Dutertre et al. and vaccinate against 
an immunodominant inhibin-α peptide in order to provide immunity against Sertoli 
cell tumors.   
 
Autoreactive T Cells 
T cells recognize antigens only when presented by molecules on the surface of 
antigen presenting cells (APC) such as macrophages and dendritic cells (Garcia 
et al., 1999).  CD4+ T cells recognize peptide antigens via their T cell receptor 
(TCR) when the peptide is presented by class II molecules of the major 
histocompatibility complex (MHC) whereas CD8+ T cells recognize peptide 
antigens when they are presented by class I molecules of the MHC (Figure 1.8).  
In most organ-specific autoimmune models, CD4+ responses predominate but 
CD8+ T cells may be involved in the self-recognition process and in the 
pathogenesis of disease typically by recognizing totally different peptide domains 
of self-proteins than those recognized by CD4+ T cells (Christianson et al., 
1993). 
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 FIGURE 1.8 Induction of an immune response.  A professional antigen 
presenting cell (APC) processes antigens into small peptides which are then 
presented on the cell surface on either MHC class I or II molecules in order to 
activate CD8+ and CD4+ T cells respectively (Therapeutic Cancer Vaccines, 
n.d.).  
 
 
Components of the adaptive immune response function by combining in a unique 
trimolecular complex that includes the T cell receptor (TCR), the MHC class I or 
class II antigen-presenting molecule, and the peptide antigen (Michels, 2013).  
The combination of these molecules initiates the adaptive immune response 
resulting in targeted immunity.  The T cell receptor must come into contact with 
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the antigen in the context of specific MHC molecules and can only then induce 
an immune response (Hess et al., 2013).  B cells, on the other hand, can become 
activated by directly engaging the antigen.  Once activated, B cells morph into 
memory and effector B cells where, as the name implies, retain “immunologic 
memory” of the antigen while the effector cells secrete antibodies that bind and 
neutralize the antigen (Hess et al., 2013).   
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CHAPTER II 
 
 
MATERIALS AND METHODS 
 
 
PEPTIDE 
 
Structure and Synthesis 
Previous studies have demonstrated that peptides containing a lysine or an 
arginine residue separated by two irrelevant amino acids from a serine residue, 
are capable of inducing a CD4+ T cell-mediated autoimmune response in mouse 
strains SWXJ, SWR/J, and SJL/J (Solares, et. al., 2004). This -KXXS- 
tetrapeptide has been successfully used in identifying immunogenic peptides of 
cardiac α-myosin heavy chain which are capable of inducing CD4+ T cell-
mediated experimental autoimmune myocarditis (Jane-wit et. al., 2002).  
 
In a previous study conducted by Altuntas et al., 2006, different peptides of 
inhibin-α were synthesized and tested for immunogenicity in mice.  The results 
showed that peptide Inα 215-234 (FLVAHTRARAPSAGERARRS) generated the 
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highest stimulation index in SWXJ (H-2q,s) and SJL/J(H-2s) mice and was found 
to be restricted by the IAs class II allele (Figure 2.1; Altuntas et al., 2006).  The 
Inα 215-234 peptide was synthesized by the Molecular Biotechnology Core 
Facility of the Lerner Research Institute using standard solid phase methodology 
and 9-fluorenylmethyloxycarbonyl (Fmoc).α-amino protected amino acids.  The 
Inα 215-234 peptide was purified >97% by reverse-phase HPLC, and amino acid 
composition was confirmed by mass spectrometry. 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.1 Inhibin-α dose response.  In a previous experiment, Altuntas et al., 
2006 determined that the peptide Inα 215-234 had the highest stimulation index 
and therefore was immunoreactive in mouse strains SWXJ and SJL. 
 
 
 
  23 
MOUSE TUMOR MODELS 
 
Autochthonous Tumor Model 
The generation of B6.D2.AMH-SV40TAg mice has been described previously 
(Dutertre et al., 1997; Figure 1.5).  For the transgenic model used in our 
experiments, B6.D2.AMH-SV40TAg (H-2b) mice were crossed with SJL/J (H-2s) 
mice purchased from The Jackson Laboratory (Bar Harbor, ME) resulting in SJL 
x B6.D2.AMH-SV40TAg (H-2b,s) mice.  The F1 progeny of SJL/J x B6.D2.AMH-
SV40TAg mice were then backcrossed with SJL/J mice for more than 20 
generations to produce SJL.AMH-SV40TAg (H-2s) transgenics (Figure 2.2).  
Male SJL.AMH-SV40TAg mice develop unilateral and bilateral Leydig cell tumors 
at around 75 weeks of age and are able to respond to the IAs-restricted Inα 215-
234.  Transgenic mice were identified by PCR amplification of a part of the hAMH 
promoter (heterologous to the murine AMH sequence) from tail DNA. 
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FIGURE 2.2 Development of transgenic SJL.AMH-SV40TAg mice.  The F1 
progeny of B6.D2.AMH-SV40TAg transgenic x SJL/J mice were backcrossed to 
SJL/J mice for more than 20 generations.  Repeated backcrossing diluted the 
B6.D2.AMH-SV40TAg haplotype background to H-2s resulting in the SJL.AMH-
SV40TAg mouse syngeneic with SJL/J and expressing the IAs class II allele 
involved in T cell presentation of the Inα 215-234 peptide. 
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Transplantable Tumor Model 
On average, it took the male SJL.AMH-SV40TAg mice we developed in our lab 
75 weeks to grow palpable tumors.  In order to accelerate our research, we 
decided to incorporate a transplantable tumor model.  The I-10 mouse testicular 
cancer cell line was obtained from the American Type Culture Collection (ATCC, 
Manassas, VA).  I-10 cells are hyperdiploid, epithelial-like Leydig cells derived 
from male BALB/c mice using a single-cell plating technique (Yasamura et al., 
1966; Shin, 1967).  Complete F-12K culture medium (ATCC) was prepared by 
supplementing it with 2.5% fetal bovine serum (Fisher Scientific, Pittsburgh, PA), 
15% horse serum (ATCC) and then filtered through a 0.2 μm Nalgene Rapid-
Flow Disposable Bottle Top Filter (Fisher Scientific).    
 
Initial I-10 Cell Thawing and Culture 
Using aseptic technique, I-10 cells were thawed in a water bath at 37°C with 
gentle agitation and periodic tube inversion.  Once the cryotube’s contents were 
partially thawed (contents should slide down tube), the cryotube was immediately 
doused with 70% ethanol and the cells were emptied into a pre-prepared 50 ml 
conical tube (Fisher Scientific) containing 30 ml of complete F-12K medium (I-
10/F-12Kc/50 ml).  The I-10 cells were rinsed by placing the I-10/F-12Kc/50 ml 
conical tube in a refrigerated tabletop centrifuge for 10 minutes at 1,500 
revolutions per minute (RPM) and 4°C.  The supernatant was aspirated and the I-
10 cells were resuspended as a single-cell suspension in 15 ml of complete F-
12K medium and placed in a 75-cm2 tissue culture flask (Fisher Scientific).  The 
  26 
I-10 cells were grown until the desired level of confluence was reached in a 
humidified 5% CO2 incubator set at 37°C. 
 
Subculturing I-10 Cells 
At 70–75% confluence, the supernatant was collected and used to rinse and 
dislodge the adherent I-10 cells with a side-to-side sweep of the serological 
pipette (Fisher Scientific).  The supernatant containing the dislodged I-10 cells 
was then placed in a 50 ml conical tube and followed by the immediate addition 
of 10 ml of 0.25% trypsin and 0.02% EDTA (Sigma Aldrich, St. Louis, MO) to the 
remaining adhered I-10 cells.  Cells were observed under an inverted microscope 
until the cell layer was dispersed (5-15 minutes).  The cells were then pipetted 
into the same 50 ml conical tube and brought up to a total volume of 30 ml using 
fresh complete F-12K medium.  The I-10 cells were rinsed by placing the I-10/F-
12Kc/50 ml conical tube in a refrigerated tabletop centrifuge for 10 minutes at 
1,500 RPM and 4°C.  The supernatant was aspirated and the I-10 cells were 
resuspended in 10 ml of complete F-12K medium and divided into two 75-cm2 
tissue culture flasks.  An extra 10 ml of complete F-12K medium was added to 
each flask to bring the final volume to 15 ml.   
 
I-10 Cell Inoculation  
At 70–75% confluence, the supernatant was collected and used to rinse and 
dislodge the adherent I-10 cells with a side-to-side sweep of the serological 
pipette.  The supernatant containing the dislodged I-10 cells was then placed in a 
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50 ml conical tube.  Next, 10 ml of 0.25% trypsin and 0.02% EDTA was added to 
the remaining adhered I-10 cells and observed under an inverted microscope 
until the cell layer was dispersed (5-15 minutes).   The cells were then pipetted 
into the same 50 ml conical tube and brought up to a total volume of 30 ml using 
fresh complete F-12K medium.  The I-10 cells were rinsed by placing the I-10/F-
12Kc/50 ml conical tube in a refrigerated tabletop centrifuge for 10 minutes at 
1,500 RPM and 4°C.  The supernatant was aspirated and the cells resuspended 
in 5 ml of D-PBS (Life Technologies, Grand Island, NY).    
 
A trypan blue viability test was performed by diluting 1 part of the I-10 single-cell 
suspension with 9 parts trypan blue (Fisher Scientific).  The solution was then 
loaded (approximately 10 μl) onto a Hausser Bright-Line Phase Hemacytometer 
(Fisher Scientific) for counting.  Once the appropriate concentration was 
achieved, 2 × 104 washed cells were inoculated subcutaneously in the left lumbar 
region of 8-10 week-old BALB/cJ males purchased from The Jackson Laboratory 
(Bar Harbor, ME).  Tumors were measured daily by Vernier caliper and their area 
calculated as length × breadth.  Mice were euthanized when the tumor reached 
17 mm in length or width.  On average, BALB/c mice developed palpable tumors 
at 30 days post inoculation (Figure 2.3).     
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FIGURE 2.3 Tumor growth following inoculation of I-10 cells into BALB/c 
mice.  Ten BALB/c male mice were inoculated and the tumors allowed to grow 
until they reached 17mm.  All error bars show ± SE.     
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Cryopreservation of I-10 Cells 
At 70–75% confluence, the supernatant was collected and used to rinse and 
dislodge the adherent I-10 cells with a side-to-side sweep of the serological 
pipette.  The supernatant containing the dislodged I-10 cells was then placed in a 
50 ml conical tube.  As described previously above, 10 ml of 0.25% trypsin and 
0.02% EDTA was added to the remaining adhered I-10 cells and observed under 
an inverted microscope until the cell layer was dispersed (5-15 minutes).  The 
cells were then pipetted into the same 50 ml conical tube and brought up to a 
total volume of 30 ml using fresh complete F-12K medium.  The I-10 cells were 
rinsed by placing the I-10/F-12Kc/50 ml conical tube in a refrigerated tabletop 
centrifuge for 10 minutes at 1,500 RPM and 4°C.  The supernatant was aspirated 
and the cells resuspended in 2 ml of freeze medium (95% complete F-12K 
medium and 5% dimethyl sulfoxide (DMSO; Fisher Scientific).  Cells from each 
75-cm2 tissue culture flask were collected and divided into 2 cryogenic tubes 
(Fisher Scientific) and frozen in 1 ml aliquots of freeze medium first in -80°C 
overnight and then transferred to liquid nitrogen for long term storage.  
 
PRODUCTION OF RECOMBINANT MOUSE INHIBIN-α 
 
Sequencing Mouse Inhibin-α 
Since the Inα 215-234 peptide used in the transgenic mouse experiments is IAs-
restricted and not immunogenic in BALB/c H-2d mice, the intact inhibin-α protein 
was used as immunogen in the BALB/c transplantable tumor model.  Mouse 
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inhibin-α is not commercially available, therefore we generated our own 
recombinant mouse inhibin-α protein (rInα).  Both online databases, Mouse 
Genome Informatics (MGI) and the National Center for Biotechnology (NCBI) 
Information, contained different nucleotide sequences of mouse inhibin-α as 
obtained from genomic analysis of C57BL/6 and DBA/2J mouse strains, 
respectively.  Thus, given these two published allelic variants of mouse inhibin-α, 
we recognized the necessity to determine the native sequence of inhibin-α in 
BALB/c mice.  
 
Total RNA was purified from both BALB/c testicles and I-10 cells using the 
RNeasy Mini Kit (Qiagen, Valencia, CA) and then stabilized in RNAlater 
(Qiagen).  Complementary DNA (cDNA) was generated using the SuperScript III 
First-Strand Synthesis SuperMix (Life Technologies) with random hexamers 
included in the kit.  The use of random hexamers is a nonspecific priming method 
that targets all RNAs in a population for first-strand cDNA synthesis.  Inhibin-α 
cDNA was amplified using the AmpliTaq Gold DNA Polymerase, LD kit (Life 
Technologies) and the primers CCTAGGCAGGAAGAGCACAG (forward) and 
ACCTCCATCTGAGGTGGTTC (reverse) with specific parameters (Table 2.1).  
Both RNA and cDNA concentrations were measured using the NanoDrop 2000 
UV-Vis Spectrophotometer (Fisher Scientific). 
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Hot Start 30 Cycles Final 
Extension 
Store 
95°C 94°C 55°C 72°C 60°C 4°C 
10 minutes 1 minute 30 seconds 1 minute 10 minutes ∞ 
 
TABLE 2.1 Reverse Transcription Polymerase Chain Reaction (RT-PCR).  
Parameters used to amplify cDNA from total RNA using the AmpliTaq Gold DNA 
Polymerase, LD kit (Life Technologies). 
 
 
 
The amplified inhibin-α cDNA was then inserted into a plasmid vector for cloning 
using the Zero Blunt TOPO PCR Cloning Kit (Life Technologies).  Escherichia 
coli strain DH5α-T1 was transformed with the pCR-Blunt II-TOPO plasmid 
containing the 1,101base pair (bp) inhibin-α cDNA sequence.  Transformed 
colonies were screened for the kanamycin resistance phenotype.  The 
recombinant plasmid was then purified using the Quantum Prep Plasmid 
Miniprep Kit (Bio-Rad, Hercules, CA) and the plasmid inspected for proper 
insertion using an XhoI digest followed by electrophoresis.  Upon verification, the 
purified plasmid was sent to the Genomics Core (Cleveland Clinic Lerner 
Research Institute, Cleveland, OH) for sequencing.  
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Recombinant Mouse Inhibin-α 
Testicular inhibin-α cDNA was inserted into the expression vector pET3a (Dapcel 
Inc., Cleveland, OH) to produce a 6X-His-tagged fusion protein in BL21 Star, E. 
coli (Life Technologies).  The transformed BL21 Star were then grown in batch 
cultures of liquid Lysogeny broth (LB) supplemented with ampicillin for a period of 
5 hours.  The His-tagged inhibin-α protein was then purified using a urea based 
lysate and nickel chromatography (Qiagen) followed by reverse-phase HPLC to 
produce endotoxin-free protein (Dudley, 2003).  The purity of rInα was gauged 
using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and Western Blot with a primary antibody specific to inhibin-α (Figure 2.4).   
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FIGURE 2.4 Production of 
mouse recombinant Inhibin-
α (rInα).  Inhibin-α cDNA was 
inserted into the expression 
vector pET3a to produce a 6 x 
His-tagged fusion protein in 
BL21 Star.  Shown here are an 
(A) SDS-PAGE coomassie gel 
and a (B) Western Blot 
depicting our purified 
recombinant inhibin-α (rInα) 
protein at 40 kDa. 
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ANALYTIC BIOCHEMISTRY ASSAYS 
 
Vaccination 
At 8-10 weeks of age, mice were immunized by subcutaneous injection in the 
abdominal flank with 100 µg of rInα protein or Inα 215-234 in 200 µL of an 
emulsion of equal volumes of water and complete Freund's adjuvant (CFA) 
containing 400 μg of Mycobacteria tuberculosis H37RA (Difco, Detroit, MI).  All 
mice were euthanized by asphyxiation with CO2 followed by cervical dislocation.  
All protocols were pre-approved by the institutional animal care and use 
committee (IACUC) of the Cleveland Clinic Foundation in compliance with the 
Public Health Service policy on humane care and use of laboratory animals. 
 
Proliferation Assay 
To determine the immunogenicity of the rInα protein and the Inα 215-234 
peptide, 10 days after immunization, axillary and inguinal lymph node cells (LNC) 
were removed, teased into single cell suspensions, washed repeatedly, and 
cultured at 3 x 105 cells/microtiter well in fetal bovine serum-supplemented 
Dulbecco’s Modified Eagle’s Medium (DMEM; Mediatech CellGro, Herndon, VA) 
at a final volume of 200 µl/well at 37°C in humidified air containing 5% CO2 in 96-
well flat-bottomed microtiter Falcon plates (Becton Dickinson Labware, Franklin 
Lakes, NJ).  At 72 hours of culture, wells were pulsed with methyl-[3H] thymidine 
(1.0 µCi/well, specific activity 6.7 Ci/mmol; PerkinElmer-New England Nuclear, 
Waltham, MA) and harvested 16 hours later by aspiration onto glass fiber filters.  
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Levels of incorporated radioactivity were determined by scintillation spectrometry.  
Results are expressed as mean counts per minute (cpm) of experimental 
cultures with antigen divided by mean cpm of cultures without antigen 
(stimulation index).  In all proliferation assays, mean cpm of cultures without 
antigen ranged between 500-2000 cpm. 
 
Enzyme Linked Immunosorbent Assay (ELISA) and Enzyme-linked 
Immunosorbent Spot Analysis (ELISpot) 
Cytokine concentrations were determined by ELISA measurement of 48-hour 
supernatants of 10-day-primed LNC cultured in supplemented DMEM at 5 x 106 
cells/well in 24-well flat-bottom Falcon plates (Fisher Scientific) in the presence of 
20 µg/ml antigen in a final volume of 2.0 ml/well.  Purified capture/detection 
antibody pairs and recombinant cytokines were obtained commercially (Fisher 
Scientific) and included anti-mouse interferon gamma (IFNγ), anti-mouse 
interleukin-17 (IL-17), and anti-mouse interleukin-5 (IL-5).  Absorbance was 
measured at 405 nm using a model 550 ELISA microplate reader (Bio-Rad).  
Standard values were plotted as absorbance vs. cytokine concentration, and 
sample cytokine concentrations were determined as values within the linear part 
of the standard curve established using known concentrations of each cytokine.  
Identical culture conditions using ELISPOT plates (Millipore, Billerica, MA) and 
capture-detection mouse IFNγ antibody pairs were used to determine 
frequencies of IFNγ–producing T cells in response to 50 μg/ml antigen or grade 
VII ovalbumin (OVA; Sigma Aldrich) as an irrelevant control antigen.  CD4+ and 
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CD8+ T cells were purified and enriched (>90%) from 3 week primed splenocytes 
by magnetic bead separation and cultured at 4–5 × 106 cells per well in 
supplemented DMEM at 2 ml per well in 24-well plates (Fisher Scientific) 
containing immunogen at 50 μg/ml.  All wells containing purified CD4+ and CD8+ 
T cells were supplemented with 4 x 106 γ-irradiated naïve syngeneic splenocytes 
(2,000 rads) acting as APCs.  Isotype-specific antibody titers to rInα were 
determined in serum samples according to manufacturer’s instructions using the 
mouse MonoAB ID/SP ELISA kit (Life Technologies).  
 
TUMOR ANALYSIS 
 
Immunocytochemistry 
After unmasking and blocking formalin-fixed, paraffin embedded tissues at 6 μm, 
different antigens were detected by immunostaining using primary antibodies 
against luteinizing hormone receptor (LHR; Santa Cruz Biotechnology, Dallas, 
TX), anti-Müllerian hormone (Abcam, San Francisco, CA), SV40 Large T Antigen 
(Santa Cruz Biotechnology), CD3 (Novacastra, Buffalo Grove, IL), all at a 
concentration of 1;1000.  Signals were detected using ImmunoCruz rabbit LSAB 
Staining System (Santa Cruz Biotechnology). 
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Adoptive Transfer 
B cells, CD4+ T cells, and CD8+ T cells were purified and enriched (>90%) from 
3 week primed splenocytes by magnetic bead separation and cultured at 4–5 × 
106 cells per well in supplemented DMEM at 2 ml per well in 24-well plates 
(Fisher Scientific) containing immunogen at 25 μg/ml.  All wells containing 
purified CD4+ and CD8+ T cells were supplemented with 4 x 106 γ-irradiated 
naïve syngeneic splenocytes (2,000 rads) acting as APCs.  After 72 hours of 
culture, cells were washed thoroughly and 2-3 x 107 cells were injected 
intraperitoneally into naïve mice in a total volume of 200 µL PBS.   
 
Isolation of Tumor Infiltrating Lymphocytes 
Lymphocytes were isolated from I-10 tumors by digestion of minced tissue for 30 
min at 37°C in Hank’s balanced salt solution (HBSS; Life Technologies) 
containing 50 Kunitz Units (KU) of DNase I (Sigma Aldrich) and 0.2 mg/ml 
collagenase II (Life Technologies).  Cells were then collected by discontinuous 
gradient centrifugation and used for flow cytometry analysis. 
 
Flow Cytometry Analysis 
Enriched TILs obtained from digestion of minced I-10 testicular tumors were 
triple-stained with CD3-specific antibody conjugated to fluorescein isothiocyanate 
(FITC) and CD44-specific antibody conjugated to cyanine 5 (Cy5) as well as 
either CD4-specific antibody conjugated to phycoerythrin (PE) or CD8-specific 
antibody conjugated to PE (Life Technologies).  TILs were double stained with 
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CD3-specific antibody conjugated to FITC and either CD4-specific antibody 
conjugated to PE or CD8-specific antibody conjugated to PE.  Data collected on 
30,000 total events were analyzed with FlowJo software (FlowJo, Ashland, OR) 
after gating on the CD3+ population. 
 
Biostatistical Analysis 
The unpaired Student t-test and one-way ANOVA were used to analyze 
differences in mean testicular tumor weights, mean change in tumor size, and 
mean ratios of cytokine expression levels in testicular tumors between mice 
immunized with Inα 215-234, rInα, or CFA.  The paired Student t-test was used 
to analyze differences between pre- and post-treatment tumor size. 
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CHAPTER III 
RESULTS 
 
Immunogenicity of Inα 215-234 
The immunogenicity of Inα 215-234 was determined using recall responses in a 
proliferation assay.  Ten days after immunization of male SJL.AMH-SV40TAg 
mice with Inα 215-234, inguinal and axillary LNC were tested for recall responses 
to the immunogen and to the irrelevant control antigen OVA.  Antigen-specific 
recall responses were elicited to Inα 215-234 but not to OVA over a wide dose 
range (Figure 3.1).  Determination of ELISpot frequencies of IFNγ-producing T 
cells also showed antigen-specific responses to Inα 215-234 from both the whole 
LNC population and from purified CD4+ T cells but not from CD8+ T cells (Figure 
3.2).  
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FIGURE 3.1 Proliferation: Recall responses of lymph node cells 10 days 
after immunization of male SJL.AMH-SV40TAg mice with Inα 215-234.  Ten 
days after immunization of male SJL.AMH-SV40TAg mice, LNC were tested for 
recall responses to the Inα 215-234 immunogen.  LNC showed antigen-specific 
recall responses to Inα 215-234 but not to OVA.  All error bars show ±SE. 
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FIGURE 3.2 ELISPOT: Frequencies of IFNγ-secreting CD4+ and CD8+ T 
cells in response to Inα 215-234.  Ten days after immunization of male 
SJL.AMH-SV40TAg mice with Inα 215-234, CD4+ and CD8+ T cells were 
purified from LNC by magnetic bead separation and tested for recall proliferative 
responses to the peptide immunogen resulting in a response predominantly from 
CD4+ T cells.  All error bars show ±SE. 
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Vaccination with Inα 215-234 Inhibits the Emergence and Growth of 
Autochthonous Leydig Cell Derived Tumors 
To determine whether a targeted autoimmune vaccination prevents the 
emergence and growth of autochthonous Leydig cell-derived tumors, we 
immunized 8-week-old male SJL.AMH-SV40TAg mice with Inα 215-234 in CFA 
or with CFA alone.  All mice in the prevention group study were euthanized at 75 
weeks of age and the tumors extracted, measured and weighed.  Our data 
indicate that mice immunized at 8 weeks of age with Inα 215-234 had a 30% 
lower mean testicular weight compared to those immunized with CFA alone 
(Figure 3.3).  We found that mice immunized at 8 weeks of age with Inα 215-234 
showed a decreased tumor incidence per mouse and per testicle with 25% of the 
treated mice being tumor free compared to 70% of the CFA immunized controls 
(Figure 3.4).  Median testicular tumor load was 5 times lower in Inα 215-234 
immunized mice and the difference in mean testicular tumor weights between 
both groups was significant (P = 0.02; Table 3.1).         
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 FIGURE 3.3 Immunization of male SJL.AMH-SV40TAg mice results in 
decreased mean testicular weight.  Male SJL.AMH-SV40TAg mice were 
immunized at 8 weeks of age with either the peptide Inα 215-234 or CFA alone 
as control mice and euthanized at 75 weeks of age.  Mice immunized with Inα 
215-234 had 30% lower testicular weight compared to control mice immunized 
with CFA (0.5 gm vs. 1.75 gm mean testicular weight, respectively).  All error 
bars show ±SE.    
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 FIGURE 3.4 Immunization of male SJL.AMH-SV40TAg mice inhibits the 
emergence of testicular tumors.  Male SJL.AMH-SV40TAg mice were 
immunized at 8 weeks of age with either Inα 215-234 or CFA alone and all mice 
were euthanized when the tumor on any mouse reached 17 mm in size.  Mice 
immunized with Inα 215-234 had a smaller mean testicle size compared to mice 
immunized with CFA alone.  All error bars show ±SE.  
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TABLE 3.1 Immunization with Inα 215-234 inhibits the emergence and 
growth of autochthonous testicular tumors in male SJL.AMH-SV40TAg 
mice.  We found that mice immunized at 8 weeks of age with Inα 215-234 
showed a decreased tumor incidence per mouse and per testicle with 75% of the 
treated mice being tumor free compared to 30% of the CFA immunized controls.  
Median testicular tumor load was 5 times lower in Inα 215-234 immunized mice 
and the difference in mean testicular tumor weights between both groups was 
significant (P = 0.02). 
 
 
 
 
 
Treatment Tumor 
Incidence in 
Mice 
Tumor 
Incidence in 
Testicles 
Median 
Testicular 
Tumor 
Weight (g) 
Mean 
Testicular 
Tumor 
Weight (g) 
CFA 10/10 14/20 (75%) 1.180 1.639 ± 0.44 
SE 
Inα 215-234 4/10 5/20 (25%) 0.235 0.489 ± 0.16 
SE 
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Immunogenicity of rInα Protein 
Next we tested the immunogenicity of rInα in male BALB/c mice by measuring 
recall proliferative responses of axillary and inguinal LNC to rInα 10 days after 
immunization.  LNC showed antigen-specific recall proliferative responses to the 
priming rInα but not to the irrelevant OVA protein (Figure 3.5). These antigen-
specific responses are also evident by ELISPOT determination of the frequencies 
of IFNγ-secreting CD4+ and CD8+ T cells reactive to the rInα protein and 
showing a predominant CD4+ response (Figure 3.6). 
 
ELISA analysis of 48-hour culture supernatants of 10 day rInα primed LNC 
showed a predominant proinflammatory cytokine response involving high 
production of IFNγ and IL-17 and virtually no production of IL-5 (Figure 3.7A).  
These data are supported by ELISPOT determination of increased frequencies of 
T cells producing the proinflammatory cytokines IFNγ and IL-17 in response to 
rInα and no increased frequencies of T cells producing the IL-5 regulatory 
cytokine (Figure 3.7B). 
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FIGURE 3.5 Proliferation: Recall responses of lymph node cells 10 days 
after immunization of male BALB/c mice with rInα.  Ten days after 
immunization of male BALB/c mice with rInα, LNC were tested for recall 
proliferative responses. The rInα protein elicited recall responses over a 
broad dose range but OVA did not.  All error bars show ±SE. 
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FIGURE 3.6 Recall proliferative responses to rInα is due primarily to 
CD4+ T cells.  Incidence of IFNγ-secreting CD4+ and CD8+ T cells that were 
reactive to the rInα protein.  Ten days after immunization of male BALB/c 
mice with rInα, CD4+ and CD8+ T cells were purified from LNC by magnetic 
bead separation and tested for recall proliferative responses to the peptide 
immunogen resulting in detection of a predominant CD4+ response.  All error 
bars show ±SE. 
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FIGURE 3.7 Immunization with rInα induces a type-1/type-17 
proinflammatory response.  (A) ELISA analysis of culture supernatants show 
production of the proinflammatory cytokines IFNγ and IL-17 but not the regulatory 
cytokine IL-5 (B) ELISPOT analysis of primed LNC shows increased frequencies 
of proinflammatory IFNγ-producing T cells and IL-17-producing T cells but no 
increased frequencies of T cells producing the regulatory cytokine IL-5.  Error 
bars show ±SE.  
A 
B 
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Vaccination with rInα Inhibits the Emergence and Growth of Transplanted I-
10 Tumors 
In our transplantable tumor model, male BALB/c mice were vaccinated at 8 
weeks of age with rInα in CFA or with CFA alone.  Seven days post 
immunization, the mice were then inoculated with I-10 Leydig cancer cells.  All 
mice were then euthanized once the first tumor in any mouse reached a length of 
17 mm in any direction.  We found that mice vaccinated against rInα had a mean 
tumor area that was 20 times smaller than control mice immunized with CFA 
alone (Figure 3.8).  The difference in mean tumor area between both groups was 
highly significant (P = 0.009).  These results provide substantial support for using 
inhibin-α vaccination to control testicular cancer.       
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FIGURE 3.8 Immunization of male BALB/c mice with rInα inhibits growth of 
transplanted testicular tumors.  Eight-week-old male BALB/c mice were 
immunized against either rInα or CFA alone and then subsequently inoculated 
with I-10 testicular tumor cells.  Vaccination with rInα significantly inhibited tumor 
growth (P = 0.009).  All error bars show ±SE.     
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Vaccination with rInα Inhibits Growth of Pre-existing Established 
Transplanted I-10 Tumors 
We then determined whether vaccination with rInα could therapeutically inhibit 
tumor growth in mice with established transplanted I-10 tumors.  In the treatment 
group, 8-week-old male BALB/c mice were inoculated with I-10 Leydig cancer 
cells and then immunized with either rInα in CFA or CFA alone.  Both 
immunizations were conducted upon detection of palpable tumors.  All mice in 
the treatment group were euthanized when the first tumor in any mouse reached 
17 mm in size.  Established transplanted tumors generally appeared 20-30 days 
after subcutaneous inoculation of 2 x 104 I-10 tumor cells.  We observed 
significant inhibition of tumor growth in mice immunized 30 days post tumor 
inoculation (P < 0.001, Figure 3.9).           
 
Tumor Immunity can be Transferred Into Naïve Recipients by rInα Primed 
CD4+ T cells and B cells but not CD8+ T cells 
To determine which lymphocyte subset responding to the vaccine is responsible 
for the observed tumor immunity, we transferred defined purified population of 
lymphocytes into naïve tumor inoculated recipients.  Eight week-old male BALB/c 
mice were immunized with either rInα or with OVA an irrelevant control 
immunogen.  Three weeks later, primed B cells, CD4+ and CD8+ T cells were 
purified from splenocytes using magnetic bead separation and cultured for 72 
hours with rInα.  The purified cells were then injected intraperitoneally into naïve 
recipient BALB/c male mice that were inoculated on the same day with I-10 
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testicular tumor cells.  Our data show that transferred rInα primed B cell and 
primed CD4+ T cells provide immunity against transplanted I-10 tumors but not 
primed CD8+ T cells (Figure 3.10A-C).  Our survival analysis showed similar 
trends.   Recipients of rInα primed B cell and primed CD4+ T cells had slower 
growing tumors but not the primed CD8+ T cell recipients (Figure 3.11A-C). 
 
 
FIGURE 3.9 Immunization of male BALB/c mice with rInα inhibits growth of 
transplanted testicular tumors.  rInα immunization of male BALB/c mice after 
detection of palpable I-10 testicular tumors results in significant inhibition of 
tumor growth (P < 0.001).  All error bars show ±SE.     
 
  54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.10 Adoptive transfer of 
primed B cells or primed CD4+ T 
cells provides immunity against 
growth of transplanted testicular 
tumors in naive BALB/c hosts.  
Eight week-old male BALB/c mice 
were vaccinated with either rInα or 
OVA.  Three weeks later, B cells 
CD4+ T cells, and CD8+ T cells 
were purified from splenocytes by 
magnetic bead separation and 
transferred into naïve recipients as 
described in the Materials and 
Methods. Recipient mice were then 
inoculated with I-10 tumor cells and 
tumor growth was assessed daily. 
Significant inhibition of tumor 
growth occurred in recipients of 
rInα-primed (A) B cells (P = 0.003), 
and (B) CD4+ T cells (P < 0.001), 
but not (C) CD8+ T cells. 
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FIGURE 3.11 Long-term 
survival analysis after 
adoptive transfer of primed B 
cells, CD4+ T cells, and CD8+ 
T cells. Recipients of rInα 
primed (A) B cells and (B) CD4+ 
T cells showed significantly 
slower growing tumors (P < 
0.001). However, (C) recipients 
of CD8+ T cells from rInα 
immunized mice did not show 
inhibited growth of inoculated I-
10 testicular tumors.   
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Serum Transfer from Mice with Primed B cells or Primed CD4+ T Cells 
Provides Immunity Against Growth of Transplanted Testicular Tumors  
In order to determine which lymphocyte subset responding to the vaccine is 
responsible for any observed tumor regulation by using a serum transfer, 8-
week-old male BALB/c mice were immunized with either rInα or OVA.  After 3 
weeks, primed B cells, CD4+ and CD8+ T cells were purified from splenocytes 
using magnetic bead separation and cultured for 72 hours with rInα.  The purified 
cells were then injected intraperitoneally into naïve mice followed by I-10 tumor 
inoculation.  Mice were euthanized and the serum collected once each mouse 
reached its endpoint (17 mm tumor size).  Serum was then injected intravenously 
into naïve male BALB/c mice.  Our data indicate that transferred serum from rInα 
primed B cell and primed CD4+ T cell mice provide immunity against 
transplanted testicular tumors but not serum from primed CD8+ T cell mice 
(Figure 3.12A-C).  Serum transfer showed similar results.  Recipients of serum 
from rInα primed B cell and primed CD4+ T cell mice had slower growing tumors 
but not the serum from primed CD8+ T cell recipient mice (Figure 3.13A-C).   
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FIGURE 3.12 Serum transfer from mice 
with primed B cells or primed CD4+ T 
cells provides immunity against growth 
of transplanted testicular tumors in 
naïve BALB/c hosts: Eight week-old male 
BALB/c mice were vaccinated with either 
rInα or OVA.  Three weeks later, B cells 
CD4+ T cells, and CD8+ T cells were 
purified from splenocytes by magnetic 
bead separation and transferred into naïve 
recipients as described in the Materials 
and Methods.  Recipient mice were then 
inoculated with I-10 tumor cells followed by 
same day intravenous serum transfer.  
Tumor growth was assessed daily. 
Significant inhibition of tumor growth 
occurred in recipients of transferred serum 
from rInα-primed (A) B cells (P < 0.001), 
and (B) CD4+ T cells (P < 0.001), but not 
(C) CD8+ T cells.  All error bars show ± 
SE.  
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Figure 3.13 Long-term 
survival analysis after serum 
transfer of primed B cells, 
CD4+ T cells, and CD8+ T 
cells: Recipients of rInα primed 
B cell and primed CD4+ T cell 
serum had significant slower 
growing tumors (P < 0.001) but 
not the primed CD8+ T cell 
recipients (A-C).   
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Vaccination with rInα Results in High Antibody Titers 
To evaluate the antibody responses induced by the vaccine with respect to their 
titers and isotype composition, ten days after immunization of male BALB/c mice 
with rInα, sera were collected and serially diluted for determining isotype titers by 
direct ELISA.  High rInα antibody titers were evident in rInα immunized mice 
(Figure 3.14).  The predominant isotypes responding to rInα included IgG1, a 
Th2-associated antibody predominantly induced by IL-4 and IgG2b, an antibody 
isotype predominantly induced by TGFβ.  Antibodies IgG3 and IgG2a, which are 
associated with a Th1 response, although negligible, IgG3 is known to have a 
major role in immune responses against protein antigens and a higher antigen 
affinity than IgG1 (Huber et. al., 2006).  IgG2a has been demonstrated to be the 
persistent antibody in the sera of BALB/c mice surviving infections (Huber et. al., 
2006).                    
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Figure 3.14 Immunization with rInα results in a high antibody titer. ELISA 
analysis of cultured supernatants show high sera antibody titers from mice 10 
days after immunization with rInα.  Serial 2-fold serum dilutions were used from 
titers 1/256 (most concentrated) to 1/8192 (most dilute).  PBS was substituted for 
diluted sera as a control.  Error bars show ±SE. 
 
 
IFNγ-Producing T cells Infiltrate Transplanted I-10 Tumors of Mice 
Vaccinated with rInα 
As we have shown, immunoregulation of testicular tumor growth is mediated at 
least in part by inhibin-α specific CD4+ T cells.  To evaluate the composition of 
infiltrates in I-10 testicular tumors, we immunostained tumor sections with CD3 
antibody.  The histology images revealed an extensive infiltration of CD3+ T cells 
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in I-10 transplanted tumors from rInα immunized mice but not from CFA 
immunized mice (Figure 3.15A, B).  Analysis of I-10 tumor infiltrates by flow 
cytometry showed high frequencies of CD3+CD4+ T cells and lower frequencies 
of CD3+CD8+ T cells. However, both CD4+ and CD8+ tumor infiltrating T cells 
expressed the CD44 activation marker (Figure 3.16A, B).     
 
 
 
 
FIGURE 3.15 Infiltration of CD3+ T cells in I-10 testicular tumors from mice 
vaccinated against rInα.  Immunocytochemical staining for CD3.  (A) Arrows 
show extensive infiltration of tumors with CD3+ T cells in male BALB/c mice 32 
days after vaccination with rInα and inoculation with I-10 cells.  (B) T cell 
infiltrates were never observed in tumor-inoculated mice immunized with CFA 
alone.  Scale bar = 50 μm. 
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FIGURE 3.16 Flow cytometry analysis of leukocytic infiltrates of I-10 
testicular tumors from male BALB/c mice vaccinated against rInα. (A) 
24.6% of all tumor infiltrating leukocytes were CD4+ T cells and the majority 
(63.7%) of these CD4+ T cells expressed the CD44 activation marker. (B) 
Although fewer of the infiltrating leukocytes were CD8+ T cells (15%), the 
majority of CD8+ T cells (73.8%) also expressed the CD44 activation marker. 
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CHAPTER IV 
DISCUSSION 
 
We show that a targeted immune response against inhibin-α is capable of 
inhibiting the growth of Leydig cell testicular tumors in mice.  Tumor growth 
inhibition was evident in both therapeutic and prophylactic settings and was 
effective against both autochthonous and transplanted tumors.  Inhibin-α 
vaccination efficiently inhibited testicular tumor growth in both SJL/J and BALB/c 
mice and the effectiveness was associated with tumor infiltrates of CD4+ T cells.  
Moreover, the tumor immunity could be transferred into naïve recipients with 
inhibin-α primed CD4+ T cells or B cells but not with primed CD8+ T cells.   
 
Dutertre et al., (1997) originally reported that expression of the SV40TAg under 
regulation of the hAMH promoter resulted in Sertoli cell-derived tumors in mice.  
However, after backcrossing for more than 20 generations from his original B6 
background to our SJL/J background, we found that the resultant autochthonous 
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tumors expressed Leydig cell markers and did not show characteristics 
consistent with Sertoli cell tumors.  Dysplasia in the SJL.AMH-SV40TAg mice 
was consistently evident within the interstitial space where the Leydig cells are 
located (Figure 4.1A,B).  Characteristics of Sertoli cell dysplasia were never 
observed in any histologic sections taken from transgenic mice backcrossed to 
the SJL/J background. 
 
Sertoli cell tumors are described in the literature as clusters of large tumor cells 
with eccentric nuclei and irregularly shaped cell membranes (Chang et al., 1998).  
In its early stages, the neoplasm is confined to the space within the seminiferous 
tubules with no apparent invasion or extension beyond the tunica albuginea 
(Chang et al., 1998).  Leydig cell tumors can be identified by their polygonal 
shape with a large, granular cytoplasm, and round nuclei with single or multiple 
nucleoli (Al-Agha & Axiotis, 2007).  Leydig cell tumors are known to metastasize 
into the lymphatic and circulatory systems (Al-Agha & Axiotis, 2007).  These well-
documented, established characteristics of Leydig tumors correlate well with the 
observed features of the autochthonous testicular tumors that grow in our 
SJL.AMH-SV40TAg transgenic mice.     
 
Moreover, our observations indicate that the tumors described by Dutertre et al. 
have several morphological characteristics that match the tumors that grow in our 
SJL.AMH-SV40TAg transgenic mice (Figure 4.2).  The neoplasm described by 
Dutertre et al. (Figure 4.2A) contains the same pattern of localized dysplasia 
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seen in the SJL.AMH-SV40TAg mouse (Figure 4.2B).   Although mild to severe 
dysplasia is seen inside the seminiferous tubules of the B6.D2AMH-SV40TAg 
mouse, most of the severe dysplasia is localized to the interstitial space where 
the Leydig cells are found.   
 
 
 
FIGURE 4.1 Comparison between normal and cancerous mouse testis: (A) 
H&E stain of normal SJL/J mouse testis at 75 weeks of age.  (B) H&E stain of 
SJL.AMH-SV40TAg mouse testis also at 75 weeks of age showing severe 
dysplasia.  Black bar = 25 μm. 
 
 
A B 
  66 
 
 
 
FIGURE 4.2 Comparison of testicular tumor from B6.D2AMH-SV40TAg and 
SJL.AMH-SV40TAg transgenic mice: (A) H&E stain (original published in black 
and white by Dutertre et al., 1997) of a normal seminiferous tubule (*) and two 
neighboring tubules devoid of germ cells and filled with proliferating Sertoli cells 
(arrows).  (B) H&E stained SJL.AMH-SV40TAg tumor with localized interstitial 
dysplasia characteristic of a Leydig cell-derived tumor. 
 
 
A B 
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Disparate observations persuaded us to investigate further and characterize the 
SJL.AMH-SV40TAg derived mouse tumor as well as normal testes from these 
transgenic mice before or after they become transformed.  Our experimental goal 
was to answer the three following fundamental questions: 
 
1) Are the SJL.AMH-SV40TAg mice tumors Sertoli or Leydig cell-derived?”  In an 
effort to determine if the testicular dysplasia originates from Leydig or Sertoli 
cells, we immunostained tumor sections using a primary antibody against LHR, a 
receptor found on Leydig cells but not on Sertoli cells.  The immunoperoxidase 
stain concentrated within the interstitial space where Leydig cells are typically 
found (Figure 4.3A) thereby supporting the view that the testicular tumor in 
SJL.AMH-SV40TAg mice is Leydig cell-derived.   
 
2) How can the AMH-SV40TAg transgene be active in Leydig cells widely 
believed not to express AMH (Guerrier et al., 1990; La Marca et al., 2010; 
Rajpert et al., 1999; Rouiller et al., 1998)?  The transgene is designed so that the 
SV40TAg transformation factor is regulated by the hAMH promoter.  To 
determine whether the AMH-SV40TAg normal pre-transformed testes expressed 
AMH, we immunostained normal pre-transformed testes sections using a primary 
antibody against AMH and observed extensive localization of the 
immunoperoxidase stain within the seminiferous tubules where Sertoli cells are 
located as well as extensive stain within the interstitial space where Leydig cells 
reside (Figure 4.3B), thereby implying that AMH is expressed in both cell types.   
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Current literature states that Leydig cells contain surface cell receptors that bind 
AMH leading to the regulation of serum testosterone (Racine et al., 1998).  If 
AMH is overexpressed, this can lead to incomplete gonadal development and a 
drop in serum testosterone levels in fetuses (Racine et al., 1998).  Investigations 
that show Leydig cells are also responsible for the production of AMH are scarce.  
Our analysis determined that AMH is also produced by Leydig cells which seems 
to be counterproductive considering the reported effect AMH has on fetal 
development and testosterone production.  These findings warrant further 
investigations into the role of Leydig cell produced AMH.              
 
3) “Are transgenic Leydig cells also expressing SV40TAg?”  Detection of the 
SV40TAg in Leydig cells implies that the hAMH promoter is active in these cells 
and that Leydig cells express AMH, an unexpected and rather novel finding. 
We immunostained normal testes from pre-transformed transgenic mice sections 
using a primary antibody against SV40Tag.  The immunoperoxidase stain 
localized to the areas where both the Sertoli and Leydig cells are found (Figure 
4.3C) indicating that both cell types express the SV40Tag and are thereby 
capable of undergoing tumorigenesis in SJL.AMH-SV40Tag transgenic mice.  
Additional immunostaining using an inhibin-α-specific primary antibody showed 
immunoperoxidase localization in both Leydig and Sertoli cells indicating that 
both cell types express inhibin-α (Figure 4.3D). 
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FIGURE 4.3 Immunocytochemical staining of SJL.AMH-SV40TAg mice 
testes: Results of staining with a primary antibody to (A) LHR as a Leydig cell 
marker, (B) AMH, (C) SV40TAg, and (D) inhibin-α.  Bar = 25 μm. 
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The results of our histological examination have led us to conclude that the 
SJL.AMH-SV40TAg mouse tumor is a Leydig cell tumor and is not Sertoli cell-
derived.  There are many possible explanations that can account for the 
observed discrepancy between our observations and prior published 
observations using mice expressing the AMH-SV40Tag transgene on a 
completely different mouse background. 
 
Backcrossing the B6 mouse to the SJL/J background may introduce variability in 
metabolism and thus gene expression.  Studies have demonstrated that 
interstrain responses to the same environment may vary due to strain-specific 
epigenetic events (Koturbash et al., 2011).   Another possibility is that the 
B6.D2AMH-SV40TAg tumor may be primarily Sertoli cell-derived while the 
SJL.AMH-SV40TAg tumor may be predominantly Leydig cell-derived.  Further 
histological analysis is needed to confirm this possibility.    
 
The importance of our study lies in the fact that we may now have a method of 
further strengthening treatment for testicular cancer and may offer an 
immunotherapy option that is currently unavailable.  If administered as adjuvant 
therapy to current standard of care, the vaccine may strengthen the body’s 
natural defenses against the cancer by eliminating any local or systemic residual 
tumor cells.  A single vaccine may potentially decrease the cost of treatment for 
testicular cancer in the USA which has been calculated to be $153-201 million in 
2013 (Glover, 2014).  Furthermore, the induced autoimmune attack seems to be 
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tolerated well in tumor-free rInα vaccinated male mice that showed no severe or 
long-lasting autoimmune inflammatory effects (Figure 4.4).   
 
There is good reason to question the efficacy of such a vaccine against testes, 
described for a long time as an “immunologically privileged site”, presumably as 
a result of the blood-testis barrier (BTB; Pelletier et al., 1981).  The BTB is a 
gating system formed by two primary components that help protect the germ 
cells from succumbing to an immune attack (Shechter et al., 2013).  The Sertoli 
cells embrace the germinal cells and interconnect with other Sertoli cells using 
tight junctions.  The Sertoli-Sertoli junction is further separated from blood 
vessels by the interstitial space formed by the seminiferous tubules (Figure 4.5).  
Leukocytes are strictly prevented from entering the lumen of the seminiferous 
tubules in order to protect the developing spermatogonia.   
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FIGURE 4.4 Normal mouse testicle immunostained with anti-CD3.  T cell 
infiltrates into the testes were not observed in wild type mice vaccinated against 
rInα.  Bar = 25 μm. 
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FIGURE 4.5 Structure of the blood-testis barrier (BTB):  Borrowed from 
(Shechter, et al., 2013). 
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The BTB represents only one component of the immune privilege in the testis.  
Within the interstitial space are Leydig cells, macrophages, and mast cells that 
secrete multiple immunosuppressive factors including growth arrest-specific gene 
6 (Gas6), IL-10, and transforming growth factor β (TGFβ) respectively (Figure 
4.5; Shechter, et al., 2013; Zhao et al., 2014).  The macrophages represent 20% 
of the total testicular interstitial cells and they play a significant role in regulating 
the development and hormonal control of the Leydig cells.  The macrophage-
Leydig cell association is also crucial in supporting testicular immune privilege 
since their intimacy results in low inflammatory responses and high 
immunosuppressive properties (Mital et al., 2011; Zhao et al., 2014).  
 
In light of this putative immune barrier, how then can we account for the 
observed lymphocytic infiltration of autochthonous and transplantable testicular 
tumors in different strains of mice and how then can primed immune cells 
mediate efficacy against the growth of such tumors in both prophylactic and 
therapeutic settings?   
 
The advantage of a Leydig cancer cell vaccine is that the targeted cells reside 
within a highly vascular area where they are in close proximity to immune cells.  
Although testicular macrophages have many characteristics that are common to 
peritoneal macrophages, they also have distinctive properties that allow them to 
interact with and regulate Leydig cell proliferation, differentiation, and 
steroidogenic functions (Hales, 2002).  Closer morphological examinations have 
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revealed that the normal macrophage-Leydig cell interaction includes 
cytoplasmic extensions (digitations) of Leydig cells that extend into membrane 
invaginations of neighboring macrophages (Christensen & Gillman, 1969; Miller 
et al., 1983).  The number of testicular macrophages increases with puberty; one 
macrophage for every four Leydig cells.  The fraction of macrophages to Leydig 
cells will increase as the number of Leydig cells increases (Hutson, 1994). 
 
Leydig cancer cells have a high metabolic rate that generates byproducts of 
mitochondrial respiration, specifically, endogenous reactive oxygen species 
(ROS).  ROS are derived from the metabolism of oxygen and normally exist in all 
aerobic cells in a homeostatic balance with antioxidants (Waris & Ahsan, 2006).  
Disruption caused by oxidative stress may result in the accumulation of 
endogenous ROS and subsequent apoptosis by reacting with membrane lipids, 
nucleotides in DNA, and sulphydryl groups in proteins (Waris & Ahsan, 2006).  
Exogenous ROS can then induce inflammatory reactions of testicular 
macrophages which respond by secreting tumor necrosis factor-alpha (TNF-α; 
Hakim, 1993).  According to Li et al., 2006, high levels of TNF-α, disrupts the 
BTB and impairs Sertoli-germ cell adhesion.           
                        
A compromised BTB and active inflammatory response are ideal conditions for 
the recruitment of inhibin-α primed T cells.  Inhibin-α is a member of the TGFβ 
superfamily and is considered to be a tumor suppressor.  The proliferative state 
of testicular neoplasms is therefore countered by increasing the production of 
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inhibin-α which then increases the T cell mediated response in a positive 
feedback loop (Risbridger et al., 2013).  Our observations confirm the infiltration 
of CD3+ T cells (Figure 3.13A) and the subsequent breakdown of the BTB 
(Figure 4.6).  The tumor lacks well-defined seminiferous tubules and components 
of the BTB.  Metastasis is evident within the enlarged blood vessels as cell-to-cell 
adhesions are lost.   
 
A possible explanation for the dissolution of normal tissue in the presence of 
cancer cells is what is known as the Warburg Effect.  The Warburg Effect states 
that most cancer cells metabolize glucose using only glycolysis followed by lactic 
acid fermentation (Dakubo, 2010).  Due to the high metabolic demand, the 
cancer cells must maximize their glucose uptake resulting in emaciated 
neighboring tissues and consequent breakdown.  Angiogenesis is important in 
the proliferation and metastatic spread of cancer cells which depend upon an 
adequate supply of oxygen and nutrients (Nishida et al., 2006). 
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FIGURE 4.6 Advanced tumor stage of a mouse testicle:  H&E stain of 
advanced SJL.AMH-SV40TAg mouse testicular tumor.  Late stage tumors were 
devoid of seminiferous tubules and a distinguishable blood-testis barrier.  Bar = 
25 μm. 
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We have found that vaccination against rInα induces a predominant CD4+ T cell 
but not CD8+ T cell response.  We know that vaccination against rInα provides 
immunity against the growth of autochthonous and transplanted testicular 
tumors.  Tumor immunity can be transferred into naïve recipients by rInα primed 
CD4+ T cells and B cells but not CD8+ T cells.   
 
Our vaccine, although designed using a recombinant protein, ultimately targets 
mouse autochthonous inhibin-α.  As previously explained, this protein plays a 
major role in the hypothalamic-pituitary axis where it is released in response to 
the binding of follicle stimulating hormone (FSH) to Sertoli cells.  If inhibin-α is 
vaccinated against, high levels of FSH may be a secondary effect of this vaccine.  
Existing evidence has demonstrated that both FSH and testosterone have a 
crucial synergistic function in the upkeep of spermatogenesis.  Specifically, FSH 
levels determine both the number of Sertoli cells and the level of sperm cell 
maintenance (Simoni et. al.,1999).   
 
It is important to note the consequence high and low levels of FSH has on the 
male reproductive system.  Past investigations have tried to identify the 
comorbidities of hyper- and hypogonadotropic hypogonadism.  This malady is 
characterized by low levels of testosterone and deficient spermatozoa.  It is 
divided into two subclasses, primary and secondary hypogonadism (Hirsch, 
2015).  Primary hypogonadism is related to a disorder of the testes while 
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secondary hypogonadism involves a defect in the hypothalamic-pituitary axis 
(Hirsch, 2015).  Some causes of primary hypogonadism are congenital in origin 
and include disorders such as Klinefelter syndrome and cryptorchidism.  These 
congenital defects are characterized by low to normal levels of testosterone 
coupled with high levels of FSH or LH (Hirsch, 2015).  In either case, the result 
tends to be a marked reduction in germ cell proliferation and infertility (Simoni et. 
al.,1999).   
 
Our results provide the basis for additional studies to determine the precise 
mechanisms involved in the tumor immunity.  Although our studies indicate that 
inhibin-α-specific CD4+ T cells or B cells mediate inhibition of testicular tumor 
growth consistent with a type 1 immune response, it is not clear how exactly 
each cell population mediates tumor growth inhibition.  It is possible that CD4+ T 
cells induce tumor cytotoxicity through direct contact similar to that occurring as a 
result of apoptotic induction through Fas/Fas ligand interactions.  Alternatively, 
CD4+ T cells may mediate tumor death signals through released soluble 
cytokines like IFNγ or TNF. It is also possible that CD4+ T cells mediate inhibition 
of tumor growth through the T cell helper function that facilitates isotype 
switching and production of inhibin-α specific antibody that may neutralize 
inhibin-α and perhaps prevent its ability to protect tumor growth.  It is also 
possible that B cells facilitate the anti-tumor features of inhibin-α-primed CD4+ T 
cells by presenting the inhibin-α antigen to the T cells thereby maintaining their 
clonal expansion through the tumor growth inhibition process.  Any one of these 
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proposed mechanisms may predominate in mediating the observed tumor 
immunity, or alternatively, several or all of these mechanisms may contribute to 
the overall induced immunity.   
 
The origin of the type1/type 2 paradigm can be traced back to breakthrough 
articles published by Dr. Christopher Parish.  He was the first scientist to 
demonstrate that the level of cell-mediated immunity (type 1) is inversely 
proportional to the humoral response (type 2) (1971, 1972, 1973).  Mosmann & 
Coffman (1987) first described subpopulations of CD4+ T cells that are now 
known as T helper type 1 (Th1) and T helper type 2 (Th2) lymphocytes.  Once 
activated, mature Th1 cells secrete IL-2, IFN-γ, and TNF-β which in turn incite 
phagocytosis, the respiratory burst, attack on intracellular pathogens, and 
upregulation of class I and class II major histocompatibility complexes (MHC), 
(Zheng et. al., 2011).  Mature Th2 cells secrete IL-4, IL-5, IL-9, IL-10, and IL-13 
resulting in B cell proliferation, high antibody production, and class switching 
(Gein et. al., 2012).  Th1 and Th2 cells also cross-regulate one another; IFN-γ 
secreted by Th1 cells suppresses IL-4 production resulting in the prevention of 
Th0 to Th2 differentiation.  Both IL-4 and IL-10 block the production of IFN-γ 
resulting in the inability of Th0 cells to differentiate into Th1 cells (Spellberg & 
Edwards, 2001).      
 
The model described above implies that type 1 responses play the leading role in 
protection against most infections.  Still other investigations suggest that 
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successful vaccines rely on a type 2 and not a type 1 immune response.  The 
latter has resulted in the traditional use of antibody titer assays to gauge vaccine-
induced protective immunity.  Three concepts described by Spellberg & Edwards 
(2001) help elucidate this paradox: 1. Although antibody levels are lower during a 
type 1 response compared to a type 2, Th1 cells can still induce an antibody-
mediated response (Mosmann & Coffman, 1987); 2. The administration of 
exogenous antibody is not the same as inducing a type 2 response since it does 
not actively suppress cell-mediated immunity but instead provides additional 
opsonins to strengthen the immune response; 3. Since most vaccine studies 
typically only assay the humoral immune response, it is difficult to gauge to what 
degree a vaccine tilts the scale towards a type 1 or a type 2 immune response. 
 
Although Parish (1971) did observe an inverse relationship between a type 1 and 
a type 2 immune response, he also stated that this same immunity can range 
from highly polarized to equivalent.  There is also evidence that the humoral 
response induced by vaccines may be consistent with a type 1 immune profile.  
When studies that looked at both cell-mediated and humoral responses were 
conducted, evidence demonstrated a predominance of a type 1 response with a 
high antibody titer of IgG1 and/or IgG3 isotypes (Hoft et. al., 1999).    
 
To help elucidate the role of B cells, if any, in the observed tumor immunity, 
BALB/cµMT/µMT mice can be used.  BALB/cµMT/µMT are homozygous for an 
inactivating mutation of the membrane exon of the immunoglobulin µ chain gene 
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and therefore lack the ability to form pre B cell receptors leaving them devoid of 
mature B cells (Hasan et. al., 2002).  These mice could be immunized as 
described earlier and the prophylactic and treatment effects gauged and 
compared.  Any resultant differences detected could then be attributed to the 
absence of mature B cells and the presence of T lymphocytes.           
 
We recognize that although our investigation showed that both CD4+ and CD8+ 
T cells infiltrated the tumor in mice immunized with inhibin-α and not in the 
control group immunized with CFA alone, we did not gauge the increase, if any, 
of these T cell infiltrates.  Furthermore, it is important to determine if any 
observed increase is due to bystander activation.  Past studies have reported 
simultaneous activation of T cells irrelevant to a targeted antigen.  This epitope 
spreading is believed to contribute to both chronic autoimmune and inflammatory 
responses (Tuohy & Kinkel, 2000).  Occurrences of this nature have been best 
characterized in murine relapsing-remitting experimental autoimmune 
encephalomyelitis.  These studies have shown evidence that the T cell repertoire 
is dynamic; new T cell recruits gain superfluous specificities (Tuohy & Kinkel, 
2000).  Although this is important for a complete investigation, it is also important 
to note that bystander activation usually only accounts for 1/200 of the specific 
cytotoxic T lymphocytes (Gilbertson et. al., 2004).            
 
From a translational perspective, it may be most useful to improve the efficacy of 
inhibin-α vaccination by incorporating reagents that block inhibitory costimulatory 
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signals thereby potentially enhancing the vaccine-induced tumor immunity.  Such 
checkpoint inhibitors include monoclonal antibodies specific for programmed 
death-1 (PD-1) and its ligand (PD-L1) as well as monoclonal antibodies specific 
for the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4; Duraiswamy et al., 
2013).  Checkpoint inhibitors and targeted cancer vaccines appear to have great 
compatibility and their incorporation as a combined cancer immunotherapy may 
continue to revolutionize control of cancer as has been recently proclaimed 
(Couzin-Frankel J, 2013). 
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